Loading...
ALXP
ALGEN
Market cap29mUSD
Oct 28, Last price  
2.10EUR
1D
-1.87%
1Q
-13.93%
Jan 2017
17.32%
IPO
-65.06%
Name

Genoway SA

Chart & performance

D1W1MN
ALXP:ALGEN chart
P/E
28.75
P/S
1.27
EPS
0.07
Vol. 1Y
40.02%
Shs. 5Y
—
Rev. 5Y
2.71%
Div Yld LY
—
Div Yld TTM
—
Revenues
21m
20,956,000
Net income
928k
928,000
CFO
-1m
-1,425,756

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

genOway S.A. is a global biotechnology enterprise that specializes in the creation, production, commercialization, and distribution of custom genetically engineered mouse, rat, and cell line models. The company develops bespoke mouse models, including knockout (KO) and knock-in (KI) types, along with customized rat models featuring constitutive and conditional KO, point mutation KI, and rapid KI options. They also engineer custom cell lines, offering constitutive KO, point mutation KI, reporter KI, quick KI, and general KI functionalities. In addition to these tailored solutions, genOway provides a comprehensive catalog of established models, such as humanized immune checkpoint mouse models, immunodeficient and reconstituted mouse and rat strains, humanized immune target models, various other pre-designed mouse and rat models, and immune checkpoint catalog cell lines. Serving a diverse range of clients, including pharmaceutical and life science companies as well as academic research institutions, genOway was founded in 1999 and is headquartered in Lyon, France.

Key people

Christian Grenier
Chairman of the Board · since 2014
Alexandre Fraichard
Chief Executive Officer · since 2014
Benjamin Bruneau
Financial and Administrative Director · since 2017
Director - Representative of Dassaut Developpement · since 2011
Laurent Fraisse
Director
Michel G. Lurquin
Director · since 2001
Denis Soubeyran
Director · since 2015
Andre Tartar
Director · since 2017
IPO date
May 04, 2007
Employees
124
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
31 RUE SAINT JEAN DE DIEU
TECHNOPARK
LYON 69007
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FY
2025‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT